BioXcel Therapeutics, Inc.

NasdaqCM:BTAI Stock Report

Market Cap: US$42.6m

BioXcel Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of BTAI?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders195,2870.632%
Private Companies480,3431.56%
Institutions1,751,3095.67%
Hedge Funds3,846,83612.5%
General Public24,603,83079.7%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 409.9%.

Top Shareholders

Top 25 shareholders own 20.08% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
6.27%
Millennium Management LLC
1,936,760US$2.7m5.53%no data
6.19%
Armistice Capital LLC
1,910,076US$2.6m563%0.07%
1.56%
BioXcel Corporation
480,343US$662.9k0%no data
0.92%
Brookfield Corporation
284,101US$392.1k0%no data
0.75%
Geode Capital Management, LLC
230,168US$317.6k11.6%no data
0.67%
Vanguard Capital Management, LLC
207,339US$286.1k0%no data
0.46%
Qatar Holding LLC
142,051US$196.0k0%no data
0.43%
Edward Jones Trust Company
131,789US$181.9k-4.29%no data
0.31%
Numeric Investors LLC
96,473US$133.1k69.8%no data
0.3%
State Street Global Advisors, Inc.
92,118US$127.1k45.7%no data
0.29%
FMR LLC
90,300US$124.6k0%no data
0.28%
Vanguard Fiduciary Trust Company
84,921US$117.2k0%no data
0.27%
BlackRock, Inc.
84,282US$116.3k-0.14%no data
0.26%
&Partners, LLC
80,864US$111.6k0%no data
0.23%
Vimal Mehta
69,942US$96.5k227%no data
0.17%
UBS Asset Management AG
52,788US$72.8k37.7%no data
0.13%
HighTower Advisors, LLC
41,000US$56.6k0%no data
0.12%
Northern Trust Global Investments
36,313US$50.1k-5.36%no data
0.087%
Javier Rodriguez
26,838US$37.0k291%no data
0.085%
Richard Steinhart
26,335US$36.3k296%no data
0.085%
Frank Yocca
26,210US$36.2k302%no data
0.066%
David Mack
20,317US$28.0k0%no data
0.061%
Beacon Pointe Advisors, LLC
18,877US$26.0k0%no data
0.053%
Osaic Wealth, Inc.
16,214US$22.4k2.95%no data
0.049%
Diversify Wealth Management, LLC
15,000US$20.7k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 10:01
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioXcel Therapeutics, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anita DushyanthBerenberg
Guyn KimBMO Capital Markets Equity Research
Alec StranahanBofA Global Research